Stemline Therapeutics KOL Event at ASH 2018

San Diego, CA, December 3, 2018

ASH_Investor_Invite_OTC_11_1_181_2_ruejdp.jpg

For more information or to RSVP, please email Alan Lada, alada@troutgroup.com

 

 

 

 

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Stemline Therapeutics, Inc. [STML] US$495 MM MCap
EL­ZON­RIS, tar­get­ed ther­a­py di­rect­ed to IL-3 re­cep­tor (CD123, ap­proved for BPDC; SL-801 an oral small molecule re­v­ersi­ble in­hibi­tor of XPO1 in Ph 1 trial; and SL-701 an im­munother­a­peu­tic that com­plet­ed Ph 2 trial in pts w/2nd line GBM [more in­for­ma­tion]

Event Contact

Alan Lada
Solebury Trout